AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation

AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation

NEKTAR THERAPEUTICS CONTACTS  
 
Nektar Investor Inquiries  
Jennifer Ruddock/Nektar Therapeutics 415-482-5585
Susan Noonan/SA Noonan Communications, LLC 212-966-3650
 
Nektar Media Inquiries  
Mary Cunney/MSL 917-208-2162
Mike Huckman/MSL 646-500-7631         
 
ASTRAZENECA CONTACTS  
 
Media Enquiries UK  
Esra Erkal-Paler +44 20 7604 8030
Vanessa Rhodes +44 20 7604 8037
 
Media  Enquiries Sweden   
Ann-Leena Mikiver +46 8 553 260 20
 
Investor Enquiries    
James Ward-Lilley +44 20 7604 8122  mob: +44 7785 432613
Karl Hard +44 20 7604 8123 mob: +44 7789 654364
Nicklas Westerholm +44 20 7604 8124  mob: +44 7585 404950
Ed Seage +1 302 886 4065    mob: +1 302 373 1361

SOURCE Nektar Therapeutics


Read more here: http://www.sacbee.com/2012/11/12/4978657/astrazeneca-announces-top-line.html#storylink=cpy

Suggested Articles

Genentech followed a $1 billion pact with Sosei Heptares with discovery deals around cancer and neurological diseases with Skyhawk and Convelo.

The partners will use wearable devices to assess how heart failure patients function and feel after being discharged from hospitals.

After spinning out two companies at the start of the year, Sosei Heptares has now inked a new deal with Roche biologics unit Genentech.